{
    "abstract": "New onset atrial fibrillation (NOAF) is a common occurrence after transcatheter aortic valve replacement (TAVR) and portends a poorer prognosis. The optimal strategy for managing NOAF in this population is uncertain.\nThis retrospective cohort study utilized deidentified patient data from the TriNetX Research Network. Patients with TAVR and NOAF were stratified into a rhythm control cohort if they were treated with antiarrhythmics, received AF ablation, or underwent cardioversion within 1 year of AF diagnosis. A rate control cohort was similarly defined by the absence of rhythm control strategies and treatment with a beta blocker, calcium channel blocker, or digoxin. After 1:1 propensity score matching, the Kaplan-Meier survival analysis and Cox proportional hazard ratios (HRs) were used to compare outcomes at 7 years of follow-up.\nWe identified 569 patients in each cohort following propensity matching. At 7 years, the primary composite outcome of all-cause death, myocardial infarction, cerebrovascular accident, and heart failure hospitalization was not significantly different between the rhythm and rate control cohorts (HR 0.99, 95% CI 0.83-1.18). The individual components of the primary outcome in addition to all-cause hospitalization were also similar between the groups.\nSimilar outcomes were seen among patients receiving an early rhythm or rate control strategy to manage NOAF after TAVR. The attenuated benefits of an early rhythm control strategy observed in this setting may be due to the overall high burden of comorbidities and advanced age of these patients.",
    "authors": [
        {
            "affiliation": "Division of Cardiovascular Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, 875 Ellicott Street Suite 7030, Buffalo, NY, 14203, USA. Kimjitae@buffalo.edu.",
            "firstname": "Jitae A",
            "initials": "JA",
            "lastname": "Kim"
        },
        {
            "affiliation": "Department of Internal Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA.",
            "firstname": "Usman S",
            "initials": "US",
            "lastname": "Najam"
        },
        {
            "affiliation": "Postgraduate Program in Cardiology and Cardiovascular Sciences, Federal University of Rio Grande do Sul, Porto Alegre, Brazil.",
            "firstname": "Caique M P",
            "initials": "CMP",
            "lastname": "Ternes"
        },
        {
            "affiliation": "Department of Cardiology, Montefiore Medical Center, New York, NY, USA.",
            "firstname": "Qussay",
            "initials": "Q",
            "lastname": "Marashly"
        },
        {
            "affiliation": "Department of Internal Medicine, Division of Cardiology, Baylor College of Medicine, Houston, TX, USA.\nCardiovascular Research Institute, Baylor College of Medicine, Houston, TX, USA.\nTexas Heart Institute at Baylor St. Luke's Medical Center, Houston, TX, USA.",
            "firstname": "Mihail G",
            "initials": "MG",
            "lastname": "Chelu"
        }
    ],
    "conclusions": null,
    "copyrights": "\u00a9 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.",
    "doi": "10.1007/s10557-024-07577-x\n10.1016/j.jacc.2013.05.015\n10.1093/eurheartj/ehw456\n10.1016/j.jcin.2022.01.018\n10.1056/NEJMoa2019422\n10.1056/NEJMoa1707855\n10.1056/NEJMoa1602002\n10.1093/aje/kwm324\n10.1161/cir.0000000000000659\n10.1001/jama.2012.96867\n10.1016/j.jacep.2022.02.014\n10.1161/JAHA.121.024214\n10.1161/circep.122.011585\n10.1161/circulationaha.122.060274\n10.3389/fcvm.2022.1050744\n10.1161/jaha.120.018978\n10.1161/cir.0000000000000040\n10.1016/j.jacc.2020.03.042\n10.1056/NEJMoa2029980\n10.1161/circulationaha.122.058575\n10.1002/jhm.445\n10.1016/j.hrthm.2014.09.049\n10.1161/CIRCULATIONAHA.121.055297\n10.1016/j.jcin.2018.05.042\n10.1161/strokeaha.121.036757\n10.1016/s0140-6736(13)62343-0\n10.1016/j.jcin.2021.05.025\n10.1056/NEJMoa2111016\n10.1016/j.ijcha.2023.101239\n10.1016/j.ijcha.2021.100910",
    "journal": "Cardiovascular drugs and therapy",
    "keywords": [
        "Antiarrhythmic",
        "Atrial fibrillation",
        "Catheter ablation",
        "Transcatheter aortic valve replacement"
    ],
    "methods": null,
    "publication_date": "2024-06-13",
    "pubmed_id": "38869743\n23727214\n27744287\n32865375\n29385358\n27043047\n18056625\n30700139\n23321761\n35589174\n36942567\n35968706\n36684588\n33960198\n24682348\n32408979\n33197159\n35726631\n19753578\n25257091\n34933570\n35109686\n24315724\n34449183\n37484063\n35146118",
    "results": "We identified 569 patients in each cohort following propensity matching. At 7 years, the primary composite outcome of all-cause death, myocardial infarction, cerebrovascular accident, and heart failure hospitalization was not significantly different between the rhythm and rate control cohorts (HR 0.99, 95% CI 0.83-1.18). The individual components of the primary outcome in addition to all-cause hospitalization were also similar between the groups.",
    "title": "Clinical Outcomes of Early Rhythm or Rate Control for New Onset Atrial Fibrillation Following Transcatheter Aortic Valve Replacement.",
    "xml": "<Element 'PubmedArticle' at 0x788502f53d30>"
}